Breast Carcinoma by Gene Expression Profile

Breast Carcinoma by Gene Expression Profile — Trials · CancerIndex

Clinical trials

Registered studies

1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 537
Recruiting: 296
Ph III recruiting: 38
Growth YoY: +1.9%
Industry share: 28%
Top sponsor: Fudan University
Termination share: 46%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (217)

clinicaltrialsPublishedShowing 101–150 of 429 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03289962	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	completed	Phase 1	273	Genentech, Inc.INDUSTRY	8	Jun 8, 2026	clinicaltrials
NCT06351332	ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC	terminated	Phase 1	7	Filipa Lynce, MDOTHER	1	Jun 4, 2026	clinicaltrials